InvestorsHub Logo
Followers 91
Posts 3296
Boards Moderated 0
Alias Born 10/18/2010

Re: starkd748 post# 2880

Friday, 05/15/2020 8:19:04 AM

Friday, May 15, 2020 8:19:04 AM

Post# of 13471
Biotech company Moderna MRNA, -0.95% has completed the phase 1 trial of its COVID-19 vaccine. A phase 2 study is expected to start this quarter and will follow 600 participants for 12 months. Significantly, Moderna announced a 10-year manufacturing deal with Swiss company Lonza Group LONN, +0.42% on Friday. The deal will enable up to 1 billion doses of the vaccine — if successful — a year. Manufacturing facilities will be set up in Switzerland and the first batch of the vaccine could be produced by July. It could be ready for market in early 2021.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News